Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02288273 · ClinicalTrials.gov registry record · Phase 4

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

A Phase 4 study of Type 2 Diabetes, sponsored by AstraZeneca.

Completed
Registry status
Phase 4
Development phase
239
Enrollment target
20
Study locations

NCT02288273 is a Phase 4 study of Type 2 Diabetes that has completed, run by AstraZeneca. The registered enrollment target is 239 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02288273, a Phase 4 study of Type 2 Diabetes, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 4
Development phase
239 participants
Enrollment target
20
Study locations

Study Summary

A Randomized, Double-blind, Parallel-group Study to Evaluate the Effect of Bydureon Compared with Placebo on 24-hour Glucose Control in Metformin-treated Patients with Type 2 Diabetes.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Placebo
  • DRUG Bydureon

Study Locations (20)

California

  • Research Site - Anaheim
  • Research Site - Chino
  • Research Site - Los Angeles
  • Research Site - North Hollywood
  • Research Site - Santa Ana
  • Research Site - Spring Valley
  • Research Site - Tustin
  • Research Site - Walnut Creek

Florida

  • Research Site - Hollywood
  • Research Site - Miami
  • Research Site - Port Orange

Ohio

  • Research Site - Franklin
  • Research Site - Marion

Georgia

  • Research Site - Marietta

Illinois

  • Research Site - Chicago

Minnesota

  • Research Site - Edina

Missouri

  • Research Site - St Louis

Montana

  • Research Site - Butte

Trial Details

FieldValue
Enrollment Target 239 participants
Start Date 2014-12
Est. Completion 2015-08
Phase Phase 4

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02288273

The ClinicalTrials.gov registry entry for NCT02288273 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (78% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02288273 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Ohio.

Frequently Asked Questions

What is clinical trial NCT02288273 about?

NCT02288273 is a clinical study titled "Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.". A Randomized, Double-blind, Parallel-group Study to Evaluate the Effect of Bydureon Compared with Placebo on 24-hour Glucose Control in Metformin-treated Patients with Type 2 Diabetes.

What is the current status of trial NCT02288273?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 239 participants. The study started on 2014-12. Estimated completion is 2015-08.

What conditions does trial NCT02288273 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT02288273?

The interventions under investigation include: Placebo (DRUG), Bydureon (DRUG).

Who is sponsoring clinical trial NCT02288273?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02288273 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.